Navigation Links
Transgenomic, Inc. Presentations to Describe High-Sensitivity Detection of Cancer Biomarkers at the 2011 American Association for Cancer Research Meeting
Date:4/1/2011

ized medicine. We are rapidly developing Ice COLD-PCR and BLOCker-Sequencing assays for important cancer genes such as EGFR, K-RAS, PIK3CA, BRAF, NRAS and TP53, and, in fact, most of these assays are already being offered to our pharmaceutical company partners through our Pharmacogenomics services laboratory in support of their clinical trial studies. Our next goal is to offer BLOCker-Sequencing assay kits for laboratories to test tumor tissue directly with a high mutation detection rate and to combine Ice COLD-PCR and BLOCker-Sequencing in kits for testing these same gene mutations in blood where the highest sensitivity is required. We believe that this combination of technologies is unique in the marketplace and will enable us to become a significant contributor in the molecular analysis and detection of cancer."

Transgenomic Presentations at AACR:

Development of a Sensitive COLD-PCR Method for the Detection of EGFR Mutations in DNA

Presenter: Katherine Richardson, Ph.D., Vice President of Research and Development

Abstract #3063. Tuesday, April 5, 8:00 AM - 12:00 PM

Use of Blocker Locked Nucleic Acid (LNA™) Oligonucleotides in Cycle Sequencing for Improved Limits of Detection (BLOCker™-Sequencing)

Presenter: Benjamin Legendre, Ph.D., Manager, Pharmacogenomics Laboratory Services

Abstract  #4855. Wednesday, April 6, 8:00 AM - 12:00 PM

About Transgenomic, Inc.

Transgenomic, Inc. (www.transgenomic.com) is a global biotechnology company specializing in high sensitivity genetic variation and mutation analysis, providing products and services in DNA mutation detection and discovery for clinical research, clinical molecular diagnostics and pharmacogenomics analyses. Product offerings include the WAVE&#
'/>"/>

SOURCE Transgenomic, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Transgenomic, Inc. Reports Third Quarter 2009 Results
2. Transgenomic, Inc. Reports Second Quarter 2009 Results
3. Transgenomic, Inc. Announces Appointment of New Board Members
4. Transgenomic, Inc. Reports First Quarter 2009 Results
5. Transgenomic, Inc. Reports Fourth Quarter and Fiscal Year 2008 Results
6. Transgenomic, Inc. Reports Third Quarter 2008 Results
7. Dendreon Announces Webcast Presentations at Four Upcoming Conferences
8. Optimer Pharmaceuticals Announces Presentations at Upcoming IDSA Annual Meeting
9. Orexigen® Therapeutics Announces Upcoming Data Presentations at the 28th Annual Scientific Meeting of The Obesity Society
10. Genomic Health Presents Six New Studies Including Four Oral Presentations in Breast, Colon and Renal Cancers at American Society of Clinical Oncology (ASCO) Annual Meeting
11. Oncothyreon announces presentations at upcoming investor conferences in June
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... Editor Note: For more information ... Moments ago, Analysts Review released new research updates concerning ... SSH ), Synergetics USA ... ELOS ), Spectranetics (NASDAQ: SPNC ), and Thoratec ... unified platform for investors, to hear about what matters - ...
(Date:3/2/2015)... Global Stem Cells Group.com ... HANK Bioengineering Co., Ltd. and its Chinese-American founder ... a stem cells training course in the City ... , Shenzhen HANK is a biotechnology company established ... and virologist, to integrate research, development, production, and ...
(Date:2/27/2015)... Halifax, Nova Scotia (PRWEB) February 27, 2015 ... has been made aware of a fraudulent press release ... GlobeNewswire, purporting to be from Immunovaccine. This press release ... with Gilead Science, Inc. The press release did ... to the information contained within the press release. ...
(Date:2/27/2015)... , Feb. 27, 2015 Research and Markets ... "Global Market Report of Trypsin" report to their ... (CAS 9002-07-7) aims at providing comprehensive data on Trypsin globally ... , North America , ... pays close attention to Trypsin This report focuses ...
Breaking Biology Technology:Quarterly Report Card of Biotechnology Companies: New Research on Sunshine Heart, Synergetics USA, Syneron Medical, Spectranetics and Thoratec 2Quarterly Report Card of Biotechnology Companies: New Research on Sunshine Heart, Synergetics USA, Syneron Medical, Spectranetics and Thoratec 3Quarterly Report Card of Biotechnology Companies: New Research on Sunshine Heart, Synergetics USA, Syneron Medical, Spectranetics and Thoratec 4Global Stem Cells Group Announces Alliance with HANK Bioengineering Co., Ltd. in Shenzhen, China 2Global Stem Cells Group Announces Alliance with HANK Bioengineering Co., Ltd. in Shenzhen, China 3Immunovaccine Disclaims Hoax Press Release 2Global Market Report of Trypsin 2014-2018 2
... to data may provide potential for label expansion in ... Inc.,(CTI) (Nasdaq: CTIC ; MTA) announced today an ... phase III Zevalin(R) ([90Y]-ibritumomab,tiuxetan) First-line Indolent Trial, FIT data. ... appropriate for CTI to begin discussions with the,U.S. Food ...
... June 17 MEDRAD, INC., announced today,that ... new Fluorodeoxyglucose (FDG),Infusion System for Positron Emission ... PET Infusion System is the,first infusion system ... the FDG,delivery process., (Logo: http://www.newscom.com/cgi-bin/prnh/20040309/MEDRADLOGO ...
... has published a,new report designed to provide critical ... stake in the market for diagnostics and treatments,in ... Insight &,Analysis: Alzheimer,s Disease," is based on in-depth ... actively involved in ongoing,research., "There is some ...
Cached Biology Technology:CTI Enters Into Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data for Potential U.S. Supplemental Marketing Application 2CTI Enters Into Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data for Potential U.S. Supplemental Marketing Application 3CTI Enters Into Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data for Potential U.S. Supplemental Marketing Application 4CTI Enters Into Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data for Potential U.S. Supplemental Marketing Application 5CTI Enters Into Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data for Potential U.S. Supplemental Marketing Application 6MEDRAD Receives FDA 510(k) Clearance for FDG Infusion System 2MEDRAD Receives FDA 510(k) Clearance for FDG Infusion System 3Thought Leaders Discuss Positive Outlook for Bapineuzumab in Alzheimer's Disease in MedPredict Report 2
(Date:2/5/2015)... Feb. 3, 2015 Despite a lack ... industries such as consumer electronics, automotive, storage and ... mount technology (SMT) screen printers. Innovations in electronics ... will push the adoption curve up. Meanwhile, sale ... as glue dispensers are indispensable in the production ...
(Date:1/22/2015)... 2015 Technology Showcase, Hall E -   EyeLock Inc. ... announced it will showcase its EyeLock ID technology integrated in ... of Energy,s Oak Ridge National Laboratory (ORNL) at ... iris identity authentication technology is being used to validate the ...
(Date:1/22/2015)... , Jan. 21, 2015  Analyst Report Issued by Small ... Brands report showed that planet-wide, transactions at merchants on the ... the total number of credit, debit, and prepaid cards reached ... were victims of fraudulent card usage in 2012, and credit ...
Breaking Biology News(10 mins):End-user Demand Spurs Global SMT Screen Printers and Glue Dispensers Market 2End-user Demand Spurs Global SMT Screen Printers and Glue Dispensers Market 3EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 2EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 3$4.80 Near Term Price Target with "Buy" given by CapRock Research for NXT-ID, Inc. (NASDAQ: NXTD) issued by Small Cap IR 2
... anaplastic lymphoma kinase, which has been reported in other ... a primary driver of the rapid metastasis that patients ... the use of anaplastic lymphoma kinase (ALK) inhibitors may ... lethal form of breast cancer. These data were ...
... scientist who is leading a multinational effort to improve ... an award for his work from the central Asian ... Academy of Natural Sciences of Drexel University, recently received ... his "significant contribution in Mongolian Environmental Science." The award ...
... press release is available in German . ... myriad smells in the air with the aid of odorant ... gene for expression. The probability that a particular receptor gene ... in total produce this receptor type. Scientists from the Max ...
Cached Biology News:Signaling pathway linked to inflammatory breast cancer may drive disease metastasis 2Gene switch for odorant receptors 2Gene switch for odorant receptors 3
Polymerase (RNA) II (DNA directed) polypeptide L...
... PI is used in conjuction with Annexin ... the earlier stages of apoptosis (Annexin V ... in later stages of apoptosis or already ... is detected in the orange range of ...
BD Primaria 35 mm Cell Culture Dish with Easy-Grip design, surface-modified polystyrene for enhanced cell culture. (20/sp, 200/ca) Packaging: 20 / sleeve, 500 / case ...
... DNA Polymerase is a premium quality recombinant ... thermostable enzyme is suitable for a wide ... highest purity and reproducible performance, each preparation ... quality control assays. NovaTaq DNA Polymerase possesses ...
Biology Products: